FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890144097> ?p ?o ?g. }

• W2890144097 abstract "AIM:The aim of this study is to develop the extended release tablet ofTrimetazidine HCL for the potential treatment of Angina Pectorise.REASONS FOR SELECTION OF TRIMETAZIDINE HCL: 1.Trimetazidine HCL (TMZ), the antianginal compound approved for clinicaluse is widely used for treatment of antianginal either alone or incombination with other antianginal agents.2. However, the main limitation to therapeutic effectiveness of TMZ is itsdose-dependent hematological toxicity, low therapeutic index, shortbiological half-life, and poor bioavailability. 3.After oral administration, it is rapidly absorbed from the gastrointestinaltract (GIT) exhibiting a peak plasma concentration of 84 ng/ml at 1.8+/- .7hrs hours. The biological half-life of TMZ is 6 hours, thus necessitatingfrequent administration (3 to 4 times a day) to maintain constant therapeuticdrug levels.REASONS FOR SELECTION OF DOSAGE FORM:1.The goal of any drug delivery system is to provide a therapeutic amount ofdrug to the proper site in the body to promptly achieve and maintain thedefined drug concentration.2.In pharmaceutical practice, drug administration to patient exists in severalapproaches, one of which is conventional, i.e. drug is given several times aday, to produce desired therapeutic effect.3.In pharmaceutical practice, drug administration to patient exists in severalapproaches, one of which is conventional, i.e. drug is given several times aday, to produce desired therapeutic effect.4.Hence the above potential problem can be minimized or reduced byformulating the drug in release control matrix i.e. sustain release system.This system minimizes or eliminates side effects, provide patient compliance, economically and promptly achieves and maintains the desiredeffect.Hence due to above properties, it may be more efficient to deliverthe drug at a sustained manner, at a reduced input rate compared with oralconventional dose occurring from a conventional release dosage formTrimetazidine HCL is available in market, presently.THE MAIN OBJECTIVE OF PRESENT STUDY:1.The present study is to investigate the possibility of developing extendedrelease dosage form for the drug Trimetazidine Hcl by using combinedpolymers i.e. HPMC k15CR with Ethyl cellulose, Metalose (Hypermellose)with Ethyl cellulose, HPMC k15CR with Metalose and Etyl Cellulose indifferent ratios as matrix. 2.It can be achieved by planning for trails until the desired release pattern isobtained. The aim is to evaluate the release profile of drug from fabricatedextended release matrix tablets.SUMMARY AND CONCLUSION:O ral route of drug administration is oldest and safest mode of drugadministration. It posses several advantages. It provides accurate dosing withoutassistantship of administration. In conventional oral drug delivery system, there is little orno control over release of drug, and effective concentration at the target site can beachieved by administration of grossly excessive dosage form. Sustained releasetechnology is relatively new field and as a consequence, research in the field has beenextremely fertile and has produced many discoveries. With many drugs, the basic goal isto achieve a steady state blood level that is therapeutically effective and non-toxic for anextended period of time. The design of proper dosage form is an important element toaccomplish this goal.Trimetazidine HCL is Vasodilator with half life of 6 hours and requiresmultiple daily doses to maintain adequate plasma concentrations. So it is selected toprepare an extended release Matrix tablet. The objective of this present study is todevelop an extended release Matrix tablet of Trimetazidine HCL which releases the drugin an extended manner over a period of 8 hours, by using different polymers and study onpolymer concentration effect on release pattern.T he present study was undertaken with an aim to formulate develop and evaluateTrimetazidine HCL extended release matrix tablets using different polymers as releaseretarding agent.Preformulation study was done initially and results directed for the further course offormulation. Based on Preformulation studies different batches of Trimetazidine HCLwere prepared using selected excipients. Powders were evaluated for tests Angle ofrepose, Bulk density, tapped density, compressibility index, and Hausner ratio beforebeing punched as tablets.IR spectra studies revealed that the drug and polymers used were compatible.Various formulations of sustained release matrix tablets of Trimetazidine HCL weredeveloped using various polymers viz, HPMC K-15CR, Hypermellose, Ethyl Cellulose indifferent proportions and combinations by Wet Granulation technique. The tablets wereevaluated for physical characterization, in vitro swelling behavior, in vitro release studyand stability studies.Observations of all formulations for physical characterization had shown that, all ofthem comply with the specifications of official pharmacopoeias and/or standardreferences.Results of in vitro release profile indicated that formulation F9 was the mostpromising formulation as the extent of drug release from this formulation was high ascompared to other formulations. Results of in-vitro swelling study indicate that theformulation F9 was having considerable swelling index.S t a bility study was conducted on tablets of Batch F9 stored at 300C (RoomTemperature) and 400C for one month. Tablets were evaluated for hardness, friability, invitrorelease profile and drug content. After one month no significant changes wereobserved in any of the studied parameters during the study period, thus it could beconcluded that formulation was stable. It was concluded that the tablets of batch F9 hadconsiderable swelling behaviors and in vitro drug release. Percentage drug release in 8 hris 80.77. It was observed that tablets of batch F9 followed the Huguchi release profiles.From the above results and discussion it is concluded that formulation of Extendedrelease matrix tablet of Trimetazidine HCL containing HPMC K-15 (19.44%) andHypermellose (19.44%), Ethyl cellulose (19.44%) batch F9 can be taken as an ideal oroptimized formulation Extended release matrix tablet for 8 hour release as it fulfills therequirements for extended release matrix tablet." @default.
• W2890144097 created "2018-09-27" @default.
• W2890144097 creator A5085844057 @default.
• W2890144097 date "2015-10-01" @default.
• W2890144097 modified "2023-09-27" @default.
• W2890144097 title "Formulation and In-Vitro Evaluation of Extended Release Matrix Tablets of Trimetazidine HCL" @default.
• W2890144097 hasPublicationYear "2015" @default.
• W2890144097 type Work @default.
• W2890144097 sameAs 2890144097 @default.
• W2890144097 citedByCount "0" @default.
• W2890144097 crossrefType "dissertation" @default.
• W2890144097 hasAuthorship W2890144097A5085844057 @default.
• W2890144097 hasConcept C112705442 @default.
• W2890144097 hasConcept C126322002 @default.
• W2890144097 hasConcept C181389837 @default.
• W2890144097 hasConcept C19831878 @default.
• W2890144097 hasConcept C2777927741 @default.
• W2890144097 hasConcept C2780035454 @default.
• W2890144097 hasConcept C71924100 @default.
• W2890144097 hasConcept C77281830 @default.
• W2890144097 hasConcept C98274493 @default.
• W2890144097 hasConceptScore W2890144097C112705442 @default.
• W2890144097 hasConceptScore W2890144097C126322002 @default.
• W2890144097 hasConceptScore W2890144097C181389837 @default.
• W2890144097 hasConceptScore W2890144097C19831878 @default.
• W2890144097 hasConceptScore W2890144097C2777927741 @default.
• W2890144097 hasConceptScore W2890144097C2780035454 @default.
• W2890144097 hasConceptScore W2890144097C71924100 @default.
• W2890144097 hasConceptScore W2890144097C77281830 @default.
• W2890144097 hasConceptScore W2890144097C98274493 @default.
• W2890144097 hasLocation W28901440971 @default.
• W2890144097 hasOpenAccess W2890144097 @default.
• W2890144097 hasPrimaryLocation W28901440971 @default.
• W2890144097 hasRelatedWork W2098069116 @default.
• W2890144097 hasRelatedWork W2184358025 @default.
• W2890144097 hasRelatedWork W2184736277 @default.
• W2890144097 hasRelatedWork W2184918534 @default.
• W2890144097 hasRelatedWork W2312593618 @default.
• W2890144097 hasRelatedWork W2328722158 @default.
• W2890144097 hasRelatedWork W2783093913 @default.
• W2890144097 hasRelatedWork W2783175243 @default.
• W2890144097 hasRelatedWork W2783253069 @default.
• W2890144097 hasRelatedWork W2783396437 @default.
• W2890144097 hasRelatedWork W2783459395 @default.
• W2890144097 hasRelatedWork W2783518183 @default.
• W2890144097 hasRelatedWork W2783788631 @default.
• W2890144097 hasRelatedWork W2784211233 @default.
• W2890144097 hasRelatedWork W2809998795 @default.
• W2890144097 hasRelatedWork W2883365895 @default.
• W2890144097 hasRelatedWork W2897158453 @default.
• W2890144097 hasRelatedWork W2187072686 @default.
• W2890144097 hasRelatedWork W2187866450 @default.
• W2890144097 hasRelatedWork W2188254595 @default.
• W2890144097 isParatext "false" @default.
• W2890144097 isRetracted "false" @default.
• W2890144097 magId "2890144097" @default.
• W2890144097 workType "dissertation" @default.